Loading…
Lobbying Spend
—
Filings
28
Firms Hired
1
Active Period
2020–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
To amend the Internal Revenue Code of 1986 for purposes of the tax on private foundation excess business holdings to treat as outstanding any employee-owned stock purchased by a business enterprise pursuant to certain employee stock ownership retirement plans.
2026 · third_quarter · Firm: VAN SCOYOC ASSOCIATES
FDA regulation, Laboratory Testing related issues H.R.8890, Clinical Laboratory Improvement Amendments (CLIA), Modernization generally H.R.5269/S.2761, Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025 (RESULTS Act), Entirety Possible Health policy package Monitor the following: Health workforce visa related issues H.R.3152/S.1546, Patent Eligibility Restoration Act of 2025, Laboratory technology related issues Possible Reconciliation, FY2027, Health related provisions Prescription drug costs, generally Public Law 117-328, Consolidated Appropriations Act, FY2023, Lab Infrastructure issues; and Diagnostic Lab Testing related issues Public Health reporting initiatives
Client expense: — · Firm income: $30,000
Matched citations: H.R.3152
To amend the Internal Revenue Code of 1986 for purposes of the tax on private foundation excess business holdings to treat as outstanding any employee-owned stock purchased by a business enterprise pursuant to certain employee stock ownership retirement plans.
2026 · third_quarter · Firm: VAN SCOYOC ASSOCIATES
FDA regulation, Laboratory Testing related issues H.R.8890, Clinical Laboratory Improvement Amendments (CLIA), Modernization generally H.R.5269/S.2761, Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025 (RESULTS Act), Entirety Possible Health policy package Monitor the following: Health workforce visa related issues H.R.3152/S.1546, Patent Eligibility Restoration Act of 2025, Laboratory technology related issues Possible Reconciliation, FY2027, Health related provisions Prescription drug costs, generally Public Law 117-328, Consolidated Appropriations Act, FY2023, Lab Infrastructure issues; and Diagnostic Lab Testing related issues Public Health reporting initiatives
Client expense: — · Firm income: $30,000
Matched citations: H.R.3152
FDA regulation, Laboratory Testing related issues H.R.8890, Clinical Laboratory Improvement Amendments (CLIA), Modernization generally H.R.5269/S.2761, Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025 (RESULTS Act), Entirety Possible Health policy package Monitor the following: Health workforce visa related issues H.R.3152/S.1546, Patent Eligibility Restoration Act of 2025, Laboratory technology related issues Possible Reconciliation, FY2027, Health related provisions Prescription drug costs, generally Public Law 117-328, Consolidated Appropriations Act, FY2023, Lab Infrastructure issues; and Diagnostic Lab Testing related issues Public Health reporting initiatives
Client expense: — · Firm income: $30,000
Matched citations: H.R.5269
FDA regulation, Laboratory Testing related issues H.R.8890, Clinical Laboratory Improvement Amendments (CLIA), Modernization generally H.R.5269/S.2761, Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025 (RESULTS Act), Entirety Possible Health policy package Monitor the following: Health workforce visa related issues H.R.3152/S.1546, Patent Eligibility Restoration Act of 2025, Laboratory technology related issues Possible Reconciliation, FY2027, Health related provisions Prescription drug costs, generally Public Law 117-328, Consolidated Appropriations Act, FY2023, Lab Infrastructure issues; and Diagnostic Lab Testing related issues Public Health reporting initiatives
Client expense: — · Firm income: $30,000
Matched citations: H.R.5269
FDA regulation, Laboratory Testing related issues H.R.8890, Clinical Laboratory Improvement Amendments (CLIA), Modernization generally H.R.5269/S.2761, Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025 (RESULTS Act), Entirety Possible Health policy package Monitor the following: Health workforce visa related issues H.R.3152/S.1546, Patent Eligibility Restoration Act of 2025, Laboratory technology related issues Possible Reconciliation, FY2027, Health related provisions Prescription drug costs, generally Public Law 117-328, Consolidated Appropriations Act, FY2023, Lab Infrastructure issues; and Diagnostic Lab Testing related issues Public Health reporting initiatives
Client expense: — · Firm income: $30,000
Matched citations: H.R.8890
FDA regulation, Laboratory Testing related issues H.R.8890, Clinical Laboratory Improvement Amendments (CLIA), Modernization generally H.R.5269/S.2761, Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025 (RESULTS Act), Entirety Possible Health policy package Monitor the following: Health workforce visa related issues H.R.3152/S.1546, Patent Eligibility Restoration Act of 2025, Laboratory technology related issues Possible Reconciliation, FY2027, Health related provisions Prescription drug costs, generally Public Law 117-328, Consolidated Appropriations Act, FY2023, Lab Infrastructure issues; and Diagnostic Lab Testing related issues Public Health reporting initiatives
Client expense: — · Firm income: $30,000
Matched citations: H.R.8890
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
2026 · third_quarter · Firm: VAN SCOYOC ASSOCIATES
Monitor the following: Public Law 119-75, Consolidated Appropriations Act, 2026, Division B - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026, Diagnostic Lab Testing related issues President's Budget FY2027 H.R.9260, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027, Diagnostic Lab Testing related issues
Client expense: — · Firm income: $30,000
Matched citations: H.R.9260
Executive Branch Comprehensive Ethics Enforcement Act
2026 · third_quarter · Firm: VAN SCOYOC ASSOCIATES
FDA regulation, Laboratory Testing related issues H.R.8890, Clinical Laboratory Improvement Amendments (CLIA), Modernization generally H.R.5269/S.2761, Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025 (RESULTS Act), Entirety Possible Health policy package Monitor the following: Health workforce visa related issues H.R.3152/S.1546, Patent Eligibility Restoration Act of 2025, Laboratory technology related issues Possible Reconciliation, FY2027, Health related provisions Prescription drug costs, generally Public Law 117-328, Consolidated Appropriations Act, FY2023, Lab Infrastructure issues; and Diagnostic Lab Testing related issues Public Health reporting initiatives
Client expense: — · Firm income: $30,000
Matched citations: S.1546
Executive Branch Comprehensive Ethics Enforcement Act
2026 · third_quarter · Firm: VAN SCOYOC ASSOCIATES
FDA regulation, Laboratory Testing related issues H.R.8890, Clinical Laboratory Improvement Amendments (CLIA), Modernization generally H.R.5269/S.2761, Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025 (RESULTS Act), Entirety Possible Health policy package Monitor the following: Health workforce visa related issues H.R.3152/S.1546, Patent Eligibility Restoration Act of 2025, Laboratory technology related issues Possible Reconciliation, FY2027, Health related provisions Prescription drug costs, generally Public Law 117-328, Consolidated Appropriations Act, FY2023, Lab Infrastructure issues; and Diagnostic Lab Testing related issues Public Health reporting initiatives
Client expense: — · Firm income: $30,000
Matched citations: S.1546
FDA regulation, Laboratory Testing related issues H.R.8890, Clinical Laboratory Improvement Amendments (CLIA), Modernization generally H.R.5269/S.2761, Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025 (RESULTS Act), Entirety Possible Health policy package Monitor the following: Health workforce visa related issues H.R.3152/S.1546, Patent Eligibility Restoration Act of 2025, Laboratory technology related issues Possible Reconciliation, FY2027, Health related provisions Prescription drug costs, generally Public Law 117-328, Consolidated Appropriations Act, FY2023, Lab Infrastructure issues; and Diagnostic Lab Testing related issues Public Health reporting initiatives
Client expense: — · Firm income: $30,000
Matched citations: S.2761
FDA regulation, Laboratory Testing related issues H.R.8890, Clinical Laboratory Improvement Amendments (CLIA), Modernization generally H.R.5269/S.2761, Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025 (RESULTS Act), Entirety Possible Health policy package Monitor the following: Health workforce visa related issues H.R.3152/S.1546, Patent Eligibility Restoration Act of 2025, Laboratory technology related issues Possible Reconciliation, FY2027, Health related provisions Prescription drug costs, generally Public Law 117-328, Consolidated Appropriations Act, FY2023, Lab Infrastructure issues; and Diagnostic Lab Testing related issues Public Health reporting initiatives
Client expense: — · Firm income: $30,000
Matched citations: S.2761
To amend the Internal Revenue Code of 1986 for purposes of the tax on private foundation excess business holdings to treat as outstanding any employee-owned stock purchased by a business enterprise pursuant to certain employee stock ownership retirement plans.
2026 · second_quarter · Firm: VAN SCOYOC ASSOCIATES
FDA regulation, Laboratory Testing related issues H.R.8890, Clinical Laboratory Improvement Amendments (CLIA), Modernization generally H.R.5269/S.2761, Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025 (RESULTS Act), Entirety Monitor the following: Possible Health policy package Health workforce visa related issues H.R.3152/S.1546, Patent Eligibility Restoration Act of 2025, Laboratory technology related issues Possible Reconciliation, FY2026 and FY2027, Health related provisions Prescription drug costs, generally Public Law 117-328, Consolidated Appropriations Act, FY2023, Lab Infrastructure issues; and Diagnostic Lab Testing related issues Public Health reporting initiatives
Client expense: — · Firm income: $30,000
Matched citations: H.R.3152
To amend the Internal Revenue Code of 1986 for purposes of the tax on private foundation excess business holdings to treat as outstanding any employee-owned stock purchased by a business enterprise pursuant to certain employee stock ownership retirement plans.
2026 · second_quarter · Firm: VAN SCOYOC ASSOCIATES
FDA regulation, Laboratory Testing related issues H.R.8890, Clinical Laboratory Improvement Amendments (CLIA), Modernization generally H.R.5269/S.2761, Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025 (RESULTS Act), Entirety Monitor the following: Possible Health policy package Health workforce visa related issues H.R.3152/S.1546, Patent Eligibility Restoration Act of 2025, Laboratory technology related issues Possible Reconciliation, FY2026 and FY2027, Health related provisions Prescription drug costs, generally Public Law 117-328, Consolidated Appropriations Act, FY2023, Lab Infrastructure issues; and Diagnostic Lab Testing related issues Public Health reporting initiatives
Client expense: — · Firm income: $30,000
Matched citations: H.R.3152
FDA regulation, Laboratory Testing related issues H.R.8890, Clinical Laboratory Improvement Amendments (CLIA), Modernization generally H.R.5269/S.2761, Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025 (RESULTS Act), Entirety Monitor the following: Possible Health policy package Health workforce visa related issues H.R.3152/S.1546, Patent Eligibility Restoration Act of 2025, Laboratory technology related issues Possible Reconciliation, FY2026 and FY2027, Health related provisions Prescription drug costs, generally Public Law 117-328, Consolidated Appropriations Act, FY2023, Lab Infrastructure issues; and Diagnostic Lab Testing related issues Public Health reporting initiatives
Client expense: — · Firm income: $30,000
Matched citations: H.R.5269
FDA regulation, Laboratory Testing related issues H.R.8890, Clinical Laboratory Improvement Amendments (CLIA), Modernization generally H.R.5269/S.2761, Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025 (RESULTS Act), Entirety Monitor the following: Possible Health policy package Health workforce visa related issues H.R.3152/S.1546, Patent Eligibility Restoration Act of 2025, Laboratory technology related issues Possible Reconciliation, FY2026 and FY2027, Health related provisions Prescription drug costs, generally Public Law 117-328, Consolidated Appropriations Act, FY2023, Lab Infrastructure issues; and Diagnostic Lab Testing related issues Public Health reporting initiatives
Client expense: — · Firm income: $30,000
Matched citations: H.R.5269
Enhancing CLIA Act of 2026
2026 · second_quarter · Firm: VAN SCOYOC ASSOCIATES
FDA regulation, Laboratory Testing related issues H.R.8890, Clinical Laboratory Improvement Amendments (CLIA), Modernization generally H.R.5269/S.2761, Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025 (RESULTS Act), Entirety Monitor the following: Possible Health policy package Health workforce visa related issues H.R.3152/S.1546, Patent Eligibility Restoration Act of 2025, Laboratory technology related issues Possible Reconciliation, FY2026 and FY2027, Health related provisions Prescription drug costs, generally Public Law 117-328, Consolidated Appropriations Act, FY2023, Lab Infrastructure issues; and Diagnostic Lab Testing related issues Public Health reporting initiatives
Client expense: — · Firm income: $30,000
Matched citations: H.R.8890
Enhancing CLIA Act of 2026
2026 · second_quarter · Firm: VAN SCOYOC ASSOCIATES
FDA regulation, Laboratory Testing related issues H.R.8890, Clinical Laboratory Improvement Amendments (CLIA), Modernization generally H.R.5269/S.2761, Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025 (RESULTS Act), Entirety Monitor the following: Possible Health policy package Health workforce visa related issues H.R.3152/S.1546, Patent Eligibility Restoration Act of 2025, Laboratory technology related issues Possible Reconciliation, FY2026 and FY2027, Health related provisions Prescription drug costs, generally Public Law 117-328, Consolidated Appropriations Act, FY2023, Lab Infrastructure issues; and Diagnostic Lab Testing related issues Public Health reporting initiatives
Client expense: — · Firm income: $30,000
Matched citations: H.R.8890
Executive Branch Comprehensive Ethics Enforcement Act
2026 · second_quarter · Firm: VAN SCOYOC ASSOCIATES
FDA regulation, Laboratory Testing related issues H.R.8890, Clinical Laboratory Improvement Amendments (CLIA), Modernization generally H.R.5269/S.2761, Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025 (RESULTS Act), Entirety Monitor the following: Possible Health policy package Health workforce visa related issues H.R.3152/S.1546, Patent Eligibility Restoration Act of 2025, Laboratory technology related issues Possible Reconciliation, FY2026 and FY2027, Health related provisions Prescription drug costs, generally Public Law 117-328, Consolidated Appropriations Act, FY2023, Lab Infrastructure issues; and Diagnostic Lab Testing related issues Public Health reporting initiatives
Client expense: — · Firm income: $30,000
Matched citations: S.1546
Executive Branch Comprehensive Ethics Enforcement Act
2026 · second_quarter · Firm: VAN SCOYOC ASSOCIATES
FDA regulation, Laboratory Testing related issues H.R.8890, Clinical Laboratory Improvement Amendments (CLIA), Modernization generally H.R.5269/S.2761, Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025 (RESULTS Act), Entirety Monitor the following: Possible Health policy package Health workforce visa related issues H.R.3152/S.1546, Patent Eligibility Restoration Act of 2025, Laboratory technology related issues Possible Reconciliation, FY2026 and FY2027, Health related provisions Prescription drug costs, generally Public Law 117-328, Consolidated Appropriations Act, FY2023, Lab Infrastructure issues; and Diagnostic Lab Testing related issues Public Health reporting initiatives
Client expense: — · Firm income: $30,000
Matched citations: S.1546
FDA regulation, Laboratory Testing related issues H.R.8890, Clinical Laboratory Improvement Amendments (CLIA), Modernization generally H.R.5269/S.2761, Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025 (RESULTS Act), Entirety Monitor the following: Possible Health policy package Health workforce visa related issues H.R.3152/S.1546, Patent Eligibility Restoration Act of 2025, Laboratory technology related issues Possible Reconciliation, FY2026 and FY2027, Health related provisions Prescription drug costs, generally Public Law 117-328, Consolidated Appropriations Act, FY2023, Lab Infrastructure issues; and Diagnostic Lab Testing related issues Public Health reporting initiatives
Client expense: — · Firm income: $30,000
Matched citations: S.2761
FDA regulation, Laboratory Testing related issues H.R.8890, Clinical Laboratory Improvement Amendments (CLIA), Modernization generally H.R.5269/S.2761, Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025 (RESULTS Act), Entirety Monitor the following: Possible Health policy package Health workforce visa related issues H.R.3152/S.1546, Patent Eligibility Restoration Act of 2025, Laboratory technology related issues Possible Reconciliation, FY2026 and FY2027, Health related provisions Prescription drug costs, generally Public Law 117-328, Consolidated Appropriations Act, FY2023, Lab Infrastructure issues; and Diagnostic Lab Testing related issues Public Health reporting initiatives
Client expense: — · Firm income: $30,000
Matched citations: S.2761
To amend the Internal Revenue Code of 1986 for purposes of the tax on private foundation excess business holdings to treat as outstanding any employee-owned stock purchased by a business enterprise pursuant to certain employee stock ownership retirement plans.
2026 · first_quarter · Firm: VAN SCOYOC ASSOCIATES
FDA regulation, Laboratory Testing related issues Clinical Laboratory Improvement Amendments (CLIA), Modernization generally H.R.5269/S.2761, Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025 (RESULTS Act), Entirety Possible Health policy package Health workforce visa related issues Monitor the following: H.R.3152/S.1546, Patent Eligibility Restoration Act of 2025, Laboratory technology related issues Possible Reconciliation, FY2026, Health related provisions Prescription drug costs, generally Public Law 117-328, Consolidated Appropriations Act, FY2023, Lab Infrastructure issues; and Diagnostic Lab Testing related issues Public Health reporting initiatives
Client expense: — · Firm income: $30,000
Matched citations: H.R.3152
To amend the Internal Revenue Code of 1986 for purposes of the tax on private foundation excess business holdings to treat as outstanding any employee-owned stock purchased by a business enterprise pursuant to certain employee stock ownership retirement plans.
2026 · first_quarter · Firm: VAN SCOYOC ASSOCIATES
FDA regulation, Laboratory Testing related issues Clinical Laboratory Improvement Amendments (CLIA), Modernization generally H.R.5269/S.2761, Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025 (RESULTS Act), Entirety Possible Health policy package Health workforce visa related issues Monitor the following: H.R.3152/S.1546, Patent Eligibility Restoration Act of 2025, Laboratory technology related issues Possible Reconciliation, FY2026, Health related provisions Prescription drug costs, generally Public Law 117-328, Consolidated Appropriations Act, FY2023, Lab Infrastructure issues; and Diagnostic Lab Testing related issues Public Health reporting initiatives
Client expense: — · Firm income: $30,000
Matched citations: H.R.3152
FDA regulation, Laboratory Testing related issues Clinical Laboratory Improvement Amendments (CLIA), Modernization generally H.R.5269/S.2761, Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025 (RESULTS Act), Entirety Possible Health policy package Health workforce visa related issues Monitor the following: H.R.3152/S.1546, Patent Eligibility Restoration Act of 2025, Laboratory technology related issues Possible Reconciliation, FY2026, Health related provisions Prescription drug costs, generally Public Law 117-328, Consolidated Appropriations Act, FY2023, Lab Infrastructure issues; and Diagnostic Lab Testing related issues Public Health reporting initiatives
Client expense: — · Firm income: $30,000
Matched citations: H.R.5269
FDA regulation, Laboratory Testing related issues Clinical Laboratory Improvement Amendments (CLIA), Modernization generally H.R.5269/S.2761, Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025 (RESULTS Act), Entirety Possible Health policy package Health workforce visa related issues Monitor the following: H.R.3152/S.1546, Patent Eligibility Restoration Act of 2025, Laboratory technology related issues Possible Reconciliation, FY2026, Health related provisions Prescription drug costs, generally Public Law 117-328, Consolidated Appropriations Act, FY2023, Lab Infrastructure issues; and Diagnostic Lab Testing related issues Public Health reporting initiatives
Client expense: — · Firm income: $30,000
Matched citations: H.R.5269
Source: Senate LDA